Shares of Novartis AG (NYSE:NVS) have been assigned a consensus recommendation of “Hold” from the twenty brokerages that are presently covering the company, Marketbeat Ratings reports. Two research analysts have rated the stock with a sell rating, eleven have given a hold rating and six have issued a buy rating on the company. The average 1 year price target among analysts that have issued a report on the stock in the last year is $83.32.

Several equities analysts have weighed in on NVS shares. TheStreet raised Novartis AG from a “c+” rating to a “b” rating in a report on Friday, June 2nd. Zacks Investment Research raised Novartis AG from a “hold” rating to a “buy” rating and set a $96.00 price objective for the company in a report on Tuesday, September 19th. Barclays PLC upgraded Novartis AG from an “underweight” rating to an “equal weight” rating in a research note on Thursday, June 22nd. Cowen and Company set a $77.00 price target on Novartis AG and gave the company a “hold” rating in a research note on Tuesday, July 11th. Finally, BidaskClub upgraded Novartis AG from a “sell” rating to a “hold” rating in a research note on Saturday, August 5th.

TRADEMARK VIOLATION WARNING: “Novartis AG (NVS) Given Consensus Rating of “Hold” by Brokerages” was first posted by Daily Political and is owned by of Daily Political. If you are reading this piece on another domain, it was stolen and reposted in violation of U.S. and international trademark and copyright law. The original version of this piece can be read at https://www.dailypolitical.com/2017/09/24/novartis-ag-nvs-given-consensus-rating-of-hold-by-brokerages.html.

Novartis AG (NYSE:NVS) last announced its quarterly earnings data on Tuesday, July 18th. The company reported $1.22 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.16 by $0.06. The firm had revenue of $12.24 billion during the quarter, compared to analysts’ expectations of $12.20 billion. Novartis AG had a return on equity of 15.51% and a net margin of 13.52%. The company’s quarterly revenue was down 1.8% compared to the same quarter last year. During the same period in the previous year, the firm earned $1.23 EPS.

In other news, major shareholder Bioventures Ltd Novartis acquired 266,667 shares of Novartis AG stock in a transaction that occurred on Wednesday, July 5th. The shares were acquired at an average price of $15.00 per share, for a total transaction of $4,000,005.00. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Insiders own 0.01% of the company’s stock.

Hedge funds have recently modified their holdings of the stock. City Holding Co. grew its position in Novartis AG by 4.6% during the 2nd quarter. City Holding Co. now owns 1,217 shares of the company’s stock worth $102,000 after acquiring an additional 54 shares during the last quarter. WFG Advisors LP grew its position in Novartis AG by 38.1% during the 2nd quarter. WFG Advisors LP now owns 1,221 shares of the company’s stock worth $102,000 after acquiring an additional 337 shares during the last quarter. TCI Wealth Advisors Inc. grew its position in Novartis AG by 20.0% during the 1st quarter. TCI Wealth Advisors Inc. now owns 1,381 shares of the company’s stock worth $103,000 after acquiring an additional 230 shares during the last quarter. Archford Capital Strategies LLC grew its position in Novartis AG by 72.3% during the 1st quarter. Archford Capital Strategies LLC now owns 1,480 shares of the company’s stock worth $110,000 after acquiring an additional 621 shares during the last quarter. Finally, Kernodle & Katon Asset Management Group LLC grew its position in Novartis AG by 3.4% during the 1st quarter. Kernodle & Katon Asset Management Group LLC now owns 1,488 shares of the company’s stock worth $111,000 after acquiring an additional 49 shares during the last quarter. Institutional investors and hedge funds own 10.93% of the company’s stock.

About Novartis AG

Novartis AG is a holding company, which provides healthcare solutions. The Company is engaged in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. The Company’s segments include Innovative Medicines, Sandoz, Alcon and Corporate activities.

Analyst Recommendations for Novartis AG (NYSE:NVS)

Receive News & Ratings for Novartis AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis AG and related companies with MarketBeat.com's FREE daily email newsletter.